Abstract. Background: Gastric cancer is one of the most common malignant tumors worldwide, and the 2nd most common in China. The development of new agents for the treatment of advanced gastric cancer ...

Abstract. Purpose: Radiation therapy continues to be an important therapeutic strategy for providing definitive local/regional control of human cancer. However, oncogenes that harbor driver mutations ...

In the early 1990s, the National Cancer Institute (NCI; Bethesda, MD) introduced a “disease-oriented” drug screening approach using a panel of 60 human cancer cell lines derived from nine different ...

Copper promotes metabolic remodeling in clear cell renal cell carcinoma by enhancing mitochondrial respiration, biosynthesis, and detoxification, fueling tumor progression and offering a target for ...

Abstract. The BCR-ABL1–negative myeloproliferative neoplasms (e.g., essential thrombocythemia, polycythemia vera, and primary myelofibrosis) are a group of heterogeneous hematologic malignancies that ...

Abstract. The large number of negative phase III trials in oncology over the last several years has renewed interest in refining phase II oncology clinical trials to maximize the chances of success in ...

AbstractSurvival rates among patients with high-risk neuroblastoma remain low and novel therapies for recurrent neuroblastomas are required. ALK is commonly mutated in primary and relapsed ...

Abstract. Preclinical models have examined the pharmacologic and pharmacodynamic activities of an anti–vascular endothelial growth factor (VEGF) humanized, monoclonal antibody, bevacizumab, and/or its ...

Estrogen receptor (ESR1) mutations have emerged as a key factor in endocrine therapy resistance. We identified and validated five novel, immunogenic ESR1-derived peptides that could be targeted ...

This issue of CCR Focus is aimed at understanding the complex issues that are involved in the conduct of phase I trials. Several innovative phase I trial designs have been proposed but in general not ...

Abstract. Immunotherapy has profoundly transformed the landscape of cancer treatment and offered therapeutic opportunities to reverse the immunosuppressive microenvironment. However, intratumoral ...

Family history of prostate cancer has traditionally been used for prostate cancer risk stratification. Here, we show that family history of prostate and breast cancer integrated with a polygenic risk ...